Recently by Reed R. Heimbecher
Life Sciences
Biosimilars: Poised to Turn to Inter Partes Review to Resolve Patent Disputes
On March 6, 2015, the U.S. Food and Drug Administration (FDA) approved the first biosimilar drug in the U.S., Sandoz’s ZarxioTM, to treat cancer patients who are at increased risk for infection. A “biosimilar” is a biological product that is highly similar to an existing FDA‑...
Read More